Search This Blog

Wednesday, December 11, 2019

BioCryst submits NDA for BCX7353

BioCryst Pharmaceuticals (NASDAQ:BCRX) has submitted a new drug application (NDA) to the FDA for approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)